Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc. is a synthetic biology platform company that sells biological R&D services and tools rather than finished end products. It operates two businesses: cell engineering, which helps customers design and optimize organisms and biological processes, and biosecurity, which provides biomonitoring and bioinformatics services to detect and track biological threats.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCustom biological R&D programs that help customers design, test, and optimize engineered cells.
Hardware, software, and related services sold to customers running more of their own R&D.
Biomonitoring, sequencing, and bioinformatics services for government and commercial surveillance programs.
Products
Reported · share of revenue- Cell Engineering Revenue78.0 %
- Services22.0 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Ginkgo sells mainly to enterprise, government, and research customers that need specialized biology capabilities they do not want to build internally. In cell engineering, buyers include pharmaceutical, biotechnology, agriculture, industrial biotech, and government organizations; in biosecurity, buyers include public health agencies, commercial operators, and international program partners. Customers use Ginkgo to reduce the cost and complexity of biological R&D, access specialized infrastructure, and outsource surveillance and analytics work.
Buy cell engineering services and tools to accelerate discovery, develop biologics, and improve developability workflows.
Buy biosecurity services and strategic R&D support for surveillance, preparedness, and national-interest programs.
Buy engineering programs to improve manufacturing processes, product performance, and environmental outcomes.
Buy engineered biology programs aimed at sustainability, resilience, and food-system improvements.
Buy biomonitoring, sequencing, and reporting services for operational surveillance and risk management.
Strategy
Ginkgo is shifting from broad, end-to-end R&D collaborations toward a more flexible platform model that includes targeted tools for customers keeping more work in-house. Management is also emphasizing biosecurity growth through biomonitoring and bioinformatics programs, while reducing dependence on legacy deal structures that relied more heavily on non-cash consideration and downstream value sharing. The strategy is to lower adoption barriers, deepen customer integration, and focus capital on the Foundry, Codebase, and cell engineering tools offerings.
Tools reduce the upfront commitment required from customers and make Ginkgo easier to integrate into existing R&D organizations.
Biosecurity can diversify revenue beyond cell engineering if Ginkgo can win recurring surveillance and analytics programs.
Management is prioritizing higher-conviction programs and reducing reliance on structures that created volatile non-cash revenue.
Geography
Ginkgo is headquartered in the United States and generates meaningful revenue from domestic customers, especially in biosecurity through CDC and XpresCheck partnerships. It also operates internationally through biosecurity programs in places such as Qatar and Ukraine, which broadens its exposure to government funding cycles, cross-border logistics, and local regulatory requirements. The business is still primarily U.S.-anchored, but international programs matter because they validate the platform and diversify end markets.
Risks
Ginkgo remains exposed to customer concentration, uneven commercialization outcomes, and the challenge of proving that its platform creates durable economic value. Biosecurity demand depends heavily on government and institutional funding, while cell engineering depends on customers advancing early-stage programs that may never reach market. The company also faces execution risk from scaling complex lab operations, supply chain dependencies, and public acceptance issues around genetically modified biology.
- Commercialization uncertaintyImpact: HighLikelihood: High
Many customer programs are early-stage, so expected milestones, royalties, or follow-on work may never materialize.
- Customer concentrationImpact: HighLikelihood: Medium
A small number of customers account for a meaningful share of revenue, so losing one can materially reduce sales and reputation.
Exposure: One Cell Engineering customer was 15% of total revenue; one Biosecurity customer was 12%
- Biosecurity funding dependenceImpact: High
Biosecurity growth relies on government, private, and multilateral funding, which can change with budgets and policy priorities.
Exposure - Operational scaling riskImpact: MediumLikelihood: Medium
The platform depends on specialized lab infrastructure, third-party suppliers, and technical execution at scale.
- Public and regulatory acceptance of engineered biologyImpact: MediumLikelihood: Medium
Ethical or legal concerns about GMOs can slow adoption and limit end-market growth.
Accounting
Judgemental itemsContracts may include multiple performance obligations, milestone payments, and royalties, affecting timing and volatility of revenue.
Impact: Can shift revenue between periods and create non-cash revenue
Some legacy arrangements included equity or convertible instruments, and terminated contracts can release deferred revenue balances.
Impact: Can inflate reported revenue without matching cash collections
Equity received from customers or partners must be valued and may later decline in value.
Impact: Affects revenue, gains/losses, and future cash realization
Payments tied to prior acquisitions or program outcomes can create earnings and cash flow volatility.
Impact: Impacts operating and financing cash flows
Similar listed companies
Publicly listed companies with a comparable business focus.
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
JinkoSolar Holding Co., Ltd.
JKS · Semiconductors & Related Devices
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
GeneDx Holdings Corp.
WGS · Services-Health Services
BioNexus Gene Lab Corp
BGLC · Services-Medical Laboratories
BioNexus Gene Lab Corp is a U.S.-listed holding company with operating subsidiaries in Malaysia that combines genomic screening services with industrial chemical trading.
MiNK Therapeutics, Inc.
INKT · Biological Products, (No Diagnostic Substances)
MiNK Therapeutics is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.
Last updated: 24/09/2026